-+ 0.00%
-+ 0.00%
-+ 0.00%

Absci reports positive interim Phase 1 data for ABS-201 antibody in HEADLINE trial

PUBT·06/24/2026 10:30:53
Listen to the news
Absci reports positive interim Phase 1 data for ABS-201 antibody in HEADLINE trial
  • Absci reported positive interim Phase 1 data for ABS-201, its first-in-human antibody targeting the prolactin receptor.
  • Blinded single-dose results have already been reviewed, showing the study drug was generally well tolerated with no serious adverse events.
  • Interim pharmacokinetics suggest dosing could be as infrequent as a few injections over six months, supporting a more convenient regimen.
  • The trial has moved into a multiple-dose phase in androgenetic alopecia participants, expanding the program beyond healthy volunteers.
  • Proof-of-concept results are expected in the second half of 2026, with full proof-of-concept data slated for early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606240630PRIMZONEFULLFEED9751729) on June 24, 2026, and is solely responsible for the information contained therein.